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Abstract
Background
Chronic kidney disease (CKD) diagnosis relies on glomerular filtration rate (eGFR) estima-
tion, traditionally using the creatinine-based Modification of Diet in Renal Disease (MDRD)
equation. The Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) equation per-
forms better in estimating eGFR and predicting mortality and CKD progression risk. Cystatin
C is an alternative glomerular filtration marker less influenced by muscle mass. CKD risk
stratification is improved by combining creatinine eGFR with cystatin C and urinary albumin
to creatinine ratio (uACR). We aimed to identify the impact of introducing CKDEPI and
cystatin C on the estimated prevalence and risk stratification of CKD in England and to de-
scribe prevalence and associations of cystatin C.
Methods and Findings
Cross sectional study of 5799 people in the nationally representative 2009 and 2010 Health
Surveys for England. Primary outcome measures: prevalence of MDRD, CKDEPI and
cystatin C-defined eGFR<60ml/min/1.73m2; prevalence of CKD biomarker combinations
(creatinine, cystatin C, uACR). Using CKDEPI instead of MDRD reduced the prevalence of
eGFR<60ml/min/1.73m2 from 6.0% (95% CI 5.4–6.6%) to 5.2% (4.7–5.8%) equivalent to
around 340,000 fewer individuals in England. Those reclassified as not having CKD evi-
denced a lower risk profile. Prevalence of cystatin C eGFR<60ml/min/1.73m2 was 7.7%
and independently associated with age, lack of qualifications, being an ex-smoker, BMI, hy-
pertension, and albuminuria. Measuring cystatin C in the 3.9% people with CKDEPI-defined
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eGFR<60ml/min/1.73m2 without albuminuria (CKD Category G3a A1) reclassified about a
third into a lower risk group with one of three biomarkers and two thirds into a group with two
of three. Measuring cystatin C in the 6.7% people with CKDEPI eGFR>60ml/min/1.73m2
with albuminuria (CKD Category G1-2) reclassified almost a tenth into a higher risk group.
Limitations
Cross sectional study, single eGFRmeasure, no measured (‘true’) GFR.
Conclusions
Introducing the CKDEPI equation and targeted cystatin C measurement reduces estimated
CKD prevalence and improves risk stratification.
Introduction
The introduction in 2002 of a definition and classification system for chronic kidney disease
(CKD) based on estimated glomerular filtration rate (eGFR) created a need for accurate meth-
ods to estimate GFR; subsequently the Modification of Diet in Renal Disease (MDRD) estimat-
ing equation was adopted worldwide.[1–4] In the UK, the National Service Framework for
Renal Services 2004/05 led to national reporting of eGFR by clinical biochemistry laboratories
from 2006 [5]; the General Practice pay for performance Quality Outcomes Framework (QOF)
included targets for CKD management from 2006/07 [6]; and the NHS Vascular Checks Pro-
gramme, introduced in 2009, includes screening for CKD (stage 3–5) in people aged 35–74
with newly identified type 2 diabetes or hypertension.[7] Nevertheless, concern has been ex-
pressed that these methods of CKD classification and identification have resulted in over-diag-
nosis and unnecessary disease-labelling and treatment, especially in the elderly.[8]
The more recently developed Chronic Kidney Disease Epidemiology Collaboration
(CKDEPI) serum creatinine (Scr) equation has been shown to improve accuracy of estimation
of eGFR and of prediction of mortality risk and risk of progression to end stage kidney disease
(ESKD) over the MDRD equation.[9,10] As a result, the 2012 Kidney Disease Improving Glob-
al Outcomes (KDIGO) recommendations advocate the routine use of the CKDEPI equation
for reporting of eGFR as do the recently revised CKD guidelines from the UK National Insti-
tute of Health and Care Excellence (NICE).[11,12]In a large retrospective study of routine cre-
atinine requests, O’Callaghan et al showed that routine use of CKDEPI Scr equation in place of
MDRD in a UK clinical biochemistry laboratory would result in a lower overall prevalence of
CKD, but an increase in higher risk CKD stage 3–5 among older people.[13] However, the
study was not able to derive population prevalence of CKD for each equation nor to assess pro-
teinuria, an important independent risk factor.[14,15]
Scr levels are affected by factors such as diet and muscle mass, and, despite the use of
weighting for age, gender and race in the eGFR estimating equations, this can result in misclas-
sification of patients.[16,17] Serum cystatin C, another marker of glomerular filtration, is less
influenced by these factors, so is an alternative for estimating GFR.[18,19] There is evidence of
its improved diagnostic accuracy for impaired renal function compared with Scr and as an in-
dependent predictor of mortality risk in older people.[20] Targeted cystatin C testing has been
recommended in the revised NICE guidelines where CKD diagnosis is uncertain.[12] National-
ly representative serum cystatin C levels have been determined in the US by analysis of samples
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from the third National Health and Nutrition Examination Survey (NHANES), but population
distributions of cystatin C and estimates of cystatin C-defined CKD in other developed coun-
tries are limited.[21] Equations combining Scr and cystatin C eGFR have shown improved ac-
curacy in CKD diagnosis, and Peralta has shown improvement in risk stratification by
combining Scr eGFR with cystatin C and albuminuria, demonstrating poorer outcomes in
those with combinations of abnormal biomarkers.[22–24]
Using nationally representative population samples (the 2009 and 2010 Health Surveys for
England (HSE)), the primary aim of this study was to examine the effect of introducing two
new measures of kidney function (CKDEPI and targeted use of cystatin C) on the estimated
prevalence of eGFR<60ml/min/1.73m2 in the general population in England. Secondary aims
were to describe the distribution and associations of cystatin C, and to explore the impact of
adding targeted cystatin C measurement to SCr eGFR and urine albumin to creatinine ratio
(uACR) measurements on the diagnosis and risk assessment of CKD.
Methods
Full details of the conduct of the HSE, measurement of non-CKD variables and response rates
are given in the HSE 2009 and 2010 reports.[25,26] In brief, a nationally representative sample
was selected each year using a stratified, two-stage sample of private addresses. Participants
completed an interview questionnaire; most consented to a nurse visit. Approval was obtained
from the Oxford B Research Ethics Committee for both surveys (HSE 2009 ref 08/H0605/103,
HSE 2010 ref 09/H0605/73).
A random urine sample was obtained from 88% of men and 86% of women aged 16 and
over who had a nurse visit, and a non-fasting blood sample from 77% of men and 73% of
women. 5799 had valid serum creatinine, 5802 had valid cystatin C (measured on stored
blood), 7592 had uACR results, and 5318 had valid results for all three markers.
Demographic factors included age, sex and ethnicity (self-reported). Ethnicity was grouped
as White, South Asian, Black and Other. Socio-economic factors selected were: i) occupation
using National Statistics Socioeconomic Classification (NSSEC, divided into three categories:
high (managerial and professional occupations), middle (intermediate occupations), and low
(routine and manual occupations)); ii) education qualifications grouped as: degree (NVQ4/
NVQ5/Degree or equivalent), below degree, and no qualification; and iii) area-level deprivation
(using Index of Multiple Deprivation 2007 (IMD) national quintiles: 1 least deprived (IMD
0.37–8.32), 2 (8.32–13.75), 3 (13.75–21.22), 4 (21.22–34.42), 5 most deprived (34.42–85.46)).
[27]
Behavioural factors included self-reported smoking, and measured body mass index (BMI,
defined as normal (<25kg/m2), overweight (25–29.9kg/m2), and obese (30kg/m2))[27] and
waist circumference (classified as:<94cm, 94–102cm (high), and>102cm (very high) for men,
and<80cm, 80–88cm (high) and>88cm (very high) for women). For South Asians, the high
waist circumference threshold was 90cm for men and 80cm for women.[28]
Clinical factors included hypertension, diabetes and cholesterol level (total and high density
lipoprotein (HDL)). Hypertension was defined as self-reported doctor diagnosis (pre-existing
diagnosis), survey-defined (identified as having high blood pressure (BP systolic140mmHg
and/or diastolic90mmHg and/or taking medication for hypertension) at the survey examina-
tion), and total (doctor + survey diagnosed). Diabetes was defined as self-reported doctor diag-
nosis (pre-existing diagnosis), survey-defined HBA1c6.5% at nurse visit, and total (doctor +
survey diagnosed). Serum total and HDL cholesterol levels were treated as continuous variables
for regression analyses.
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Kidney function
Serum creatinine was assayed using an IDMS traceable enzymatic assay in a single laboratory
(Clinical Biochemistry Department at the Royal Victoria Infirmary (RVI), Newcastle-upon-
Tyne). Standard formulae were used to calculate MDRD and CKDEPI equations.[2,9] Albumin-
uria was measured on a single random urine sample and any albuminuria was defined as uACR
>2.5mg/mmol in men and>3.5 in women (an artefact in the way normal uACR was recorded
in the survey precluded use of the gender-independent KDIGO definition of>3mg/mmol).[1,3]
Details of laboratory analysis, internal quality control, and external quality assurance are provid-
ed in HSE documentation.[25,26] The Roche Tina-quant immuno-turbidimetric assay was used
to measure cystatin C.[29] The Grubb equation was used to derive eGFR from cystatin C values.
[30] As a sensitivity analysis we also derived a threshold cystatin C level to compare with CKD
defined by Grubb eGFR. Individuals in age grouping 16–34 with no hypertension, no diabetes
and no albuminuria and CKDEPI eGFR60ml/min/1.73m2 were selected to determine a cut off
value for increased cystatin C levels. This method is similar to that previously used in analysis of
NHANES data.[21] The KDIGO classification of CKD was used to categorise eGFR.[1] Where
numbers were small, individuals were categorised into four eGFR groups to allow for comparison
between cystatin C and SCr-based eGFR categories (90ml/min/1.73m2; 60–89ml/min/1.73m2;
45–59ml/min/1.73m2 (G3a); and<45ml/min/1.73m2). Those with eGFR>60ml/min/1.73m2
were combined for the purposes of analysis.
Statistical analysis
Descriptive statistics were used to compare the socio-demographic and clinical characteristics
of the study population, including the distribution of cystatin C values. Overall and age-sex ad-
justed prevalence of eGFR<60ml/min/1.73m2 was compared by eGFR calculation method
(MDRD vs. CKDEPI). Estimated (age-sex adjusted) numbers of people with CKD in England
was derived for each method using 2011 Census data.[31]
The distribution of biomarkers in the study population was summarised using a method
similar to that used by Peralta et al.[24] We identified the change in future potential risk (using
Peralta’s categories of biomarker combinations) by the count of combinations of three bio-
markers (CKDEPI Scr eGFR<60ml/min/1.73m2, uACR 3mg/mmol and cystatin C eGFR
<60ml/min/1.73m2) and summarised the effect on stratification of people in the following
groups:
a) People with one abnormal biomarker (creatinine based eGFR<60ml/min/1.73m2 but with-
out albuminuria or creatinine based eGFR>60ml/min/1.73m2 with albuminuria) reclassified
as one or two biomarkers by having cystatin C eGFR greater or less than 60ml/min/1.73m2:
b) People with two biomarkers (creatinine-based eGFR<60ml/min/1.73m2 and albuminuria) re-
classified as two or three biomarkers by having cystatin C eGFR greater or less than 60ml/min/
1.73m2:
Univariate, age-sex adjusted, and multivariable logistic regression models were used to ex-
amine the associations between cystatin C eGFR (Grubb) and demographic, socio-economic,
lifestyle and clinical factors. Age/sex, age/socioeconomic status, and age/diabetes interactions
were tested.
Overall CKD prevalence estimation accounted for weighting within gender to allow for gen-
der differences in response. Odds ratios are presented with 95% confidence intervals (CIs) and
Using NewMeasures to Estimate CKD Prevalence in England
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p values<0.05 are considered statistically significant unless otherwise stated. All analyses were
performed using IBM SPSS Statistics version 19.
Results
The household response rates of the 2009 and 2010 HSE were 68% and 66% respectively.
[24,25] The study population consisted of 5799 individuals (5786 weighted population) with
both serum creatinine and cystatin C results. 3186/5799 (55%) were women and 2613/5799
(45%) were men; they were predominantly white; and the median age was 50 (interquartile
range 38–64) (Table 1). These characteristics were similar for 7952 people with a valid uACR
and 5260 with all three biomarkers.
Effect on estimated prevalence of introducing new measures of kidney
function
Use of the CKDEPI Scr equation classified fewer individuals as having eGFR<60ml/min/1.73m2
than the MDRD equation (5.2% vs. 6.0%, Table 2). About 1% of all individuals would be classi-
fied as having CKD G3-5 by the MDRD equation that would not by CKDEPI, compared with
only 0.2% for CKDEPI equation. Estimated prevalence was lower in both sexes using the
CKDEPI Scr equation but this varied by age, with a higher estimated prevalence in people over
75 (Fig. 1). People reclassified by CKDEPI as not having eGFR<60ml/min/1.73m2 were more
likely to be younger, female, and less likely to have factors associated with poorer outcome
such as diabetes, hypertension and albuminuria. Based on 2011 Census data, the estimated
number of adults aged 16 and above with eGFR<60ml/min/1.73m2 in England was 2.59 mil-
lion (MDRD) and 2.25 million (CKDEPI). A change from routine use of MDRD to CKDEPI
would therefore result in over 340,000 fewer adults having eGFR<60ml/min/1.73m2 in
England.
The prevalence of cystatin C-derived eGFR<60ml/min/1.73m2 was 447/5786 (7.7%), higher
than both CKDEPI and MDRD equations. Measurement of uACR and cystatin C in addition
to CKDEPI eGFR reduced those classified as having potential moderate CKD (KDIGO catego-
ries G3a and 3b) to 230 (estimated prevalence 4%, Table 2).[3] Fig. 2 summarises the effect of
the use of the different measures on the risk profile and estimated prevalence of CKD among
those tested for all three biomarkers (n = 5260). In total, 799/5260 (15.2%) had at least one
abnormal biomarker. Applying cystatin C to people with CKDEPI-defined eGFR<60ml/min/
1.73m2 (representing possible CKD category G 3–5) and people with CKDEPI-defined eGFR
60ml/min/1.73m2 (representing CKD category G 1–2) resulted in the following CKD groups:
In the 207 (3.9%) people with CKDEPI-defined eGFR<60ml/min/1.73m2 without albumin-
uria (CKD Category G3a A1) about a third (77, 1.4% of total) were reclassified into a lower risk
group with one of three biomarkers and two thirds (130, 2.5% of total) into a group with two of
three. Among people aged over 75, there were 91 with CKDEPI-defined eGFR<60ml/min/1.73m2
without albuminuria (CKD Category G3a A1). Of those, 22 (24.2%) were reclassified as having
no CKD by the addition of cystatin C eGFR.
In the 355 (6.7%) people with CKDEPI eGFR60ml/min/1.73m2 with albuminuria (CKD
Category G1-2) almost a tenth (34, 0.6% of total) were reclassified into a higher risk group with
two positive biomarkers.
In the 66 (1.3%) people with CKDEPI-defined eGFR<60ml/min/1.73m2 and albuminuria
(CKD Category G3-5 A2-3) over 85% (57,1.1% of total) had all three biomarkers when cystatin
C measurement was added.
Table 3 compares some key characteristics of individuals with albuminuria only and
CKDEPI eGFR<60ml/min/1.73m2 only with those who have combinations of abnormal
Using NewMeasures to Estimate CKD Prevalence in England
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Table 1. Sociodemographic and clinical characteristics of the weighted study sample.
Variable Category People with valid serum creatinine and
cystatin c value
Number (%) in category
All Aged 16+ 5799 (100%)
Age Age 16–34 1756 (30.3%)
Age 34–54 2037 (35.2%)
Age 55–64 856 (14.8%)
Age 65–74 615 (10.6%)
Age 75+ 522 (9.0%)
Ethnicity White 5244 (90.7%)
South Asian 243 (4.2%)
Black 154 (2.7%)
Other 139 (2.4%)
Sex Male 2823 (48.8%)
Female 2963 (51.2%)
Occupation (NS-SEC) High 1894 (33.1%)
Middle 1203 (21.0%)
Low 2619 (45.8%)
Qualiﬁcation Degree 1295 (22.4%)
Below degree 3296 (57.0%)
None 1197 (20.6%)
IMD quintile (1 = least deprived, 5 = most deprived) 1. (IMD 0.37–8.32) 1197 (20.7%)
2. (IMD 8.32–13.75) 1204 (20.8%)
3. (IMD 13.75–21.22) 1228 (21.2%)
4. (IMD 21.22–34.42) 1105 (19.1%)
5. (IMD 34.42–85.46) 1051 (18.2%)
Smoking Never 3126 (54.2%)
Ex 1429 (24.8%)
Current 1210 (21.0%)
Body mass index (BMI) (kg/m2) Mean ±SD 27.14 ±5.06
BMI categories Normal 1956 (36.8%)
Overweight 2047 (38.5%)
Obese 1314 (24.7%)
Waist circumference (cm) Mean ±SD 92.92 ±14.01
Waist circumference categories Low 2120 (37.1%)
High 1347 (23.6%)
Very High 2242 (39.3%)
Total cholesterol (mmol/L) Mean ±SD 5.30 ±1.44
Total cholesterol categories < 5mmol/L 2675 (46.2%)
 5mmol/L 3110 (53.8%)
HDL cholesterol (mmol/L) Mean ±SD 1.48 ±0.43
HDL cholesterol categories < 1.2mmol/l 1301 (22.5%)
 1.2mmol 4485 (77.5%)
Albuminuria None 4837 (92.0%)
Micro 399 (7.6%)
Macro 22 (0.4%)
(Continued)
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Table 1. (Continued)
Variable Category People with valid serum creatinine and
cystatin c value
Number (%) in category
All Aged 16+ 5799 (100%)
Diabetes No diabetes 5370 (92.6%)
Doctor diagnoseda 305 (5.3%)
Survey deﬁned b 316 (5.5%)
Total c 429 (7.4%)
Hypertension No hypertension 3800 (65.5%)
Doctor diagnosed a 1387 (23.9%)
Survey deﬁned d 1542 (26.6%)
Total c 1980 (34.1%)
Figures are number (%) unless stated otherwise
a Self-reported doctor diagnosis
b HBA1c 6.5%
cDoctor or survey diagnosed
d Identiﬁed as high blood pressure (BP systolic 140mmHg and/or diastolic 90mmHg and/or taking medication for hypertension)
NS-SEC: National Statistics Socioeconomic Classiﬁcation
IMD: Index of Multiple Deprivation
BMI: Body Mass Index
HDL: High Density Lipoprotein.
doi:10.1371/journal.pone.0118676.t001
Table 2. Sociodemographic and clinical characteristics of people with CKD 3–5 deﬁned by eGFR (from MDRD and CKDEPI equations) and after
targeted addition of cystatin C.
MDRD eGFR <60ml/
min/1.73m2
CKDEPI eGFR <60ml/
min/1.73m2
At least two biomarkers
(CKDEPI eGFR <60ml/
min/1.73m2, uACR> =
3mg/mmol, cystatin C
eGFR <60ml/min/
1.73m2)
Total in category 349 / 5786 303 / 5786 230 / 5786
% of study total (95% conﬁdence
intervals)
6 (5.4–6.6) 5.2 (4.7–5.8) 4.0 (3.5–4.5)
n column % n column % n column %
Sex Male 135 38.7 126 41.6 115 50.0
Female 214 61.3 177 58.4 115 50.0
Age 16–54 46 13.1 21 6.9 10 4.3
55+ 303 86.9 282 93.1 220 95.7
Diabetes (total) 70 20.1 66 21.9 59 25.7
Hypertension (total) 241 61.9 224 74.2 183 79.6
Albuminuria A1 246 79.1 207 75.9 128 55.7
A2 and A3 65 20.9 66 24.1 102 44.3
eGFR: Estimated glomerular ﬁltration rate
MDRD: Modiﬁcation of diet in renal disease
CKDEPI: Chronic Kidney Disease Epidemiology Collaboration
uACR: Urinary albumin to creatinine ratio.
doi:10.1371/journal.pone.0118676.t002
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markers. Although the numbers are small, this suggests that those with albuminuria and cysta-
tin C abnormalities tend to be older, male and a higher proportion have hypertension than
those with albuminuria alone. It also suggests that those with creatinine as well as cystatin C
abnormality tend to be older and have a higher proportion with diabetes and hypertension
than those with creatinine<60ml/min/m2 alone.
Distributions and associations of cystatin C
The mean cystatin C level was 0.96mg/L (SD 0.27) and median 0.92mg/L (IQR 0.82–1.03)
Distribution of cystatin C varied by age and sex. At younger ages, males had higher median
cystatin C than females, but this gender difference narrowed as age increased. In univariate
analyses, increasing age, lack of qualifications, smoking, increasing BMI, diabetes, hyperten-
sion, total cholesterol, HDL cholesterol were all significantly positively associated with cystatin
C eGFR<60ml/min/1.73m2. In the fully adjusted model, increasing age, lack of qualifications,
being an ex-smoker, increasing BMI, diabetes, hypertension, and albuminuria remained associ-
ated (Table 4). There were similar associations for elevated cystatin C using the derived thresh-
old 1.2mg/l. There were no significant interactions.
Fig 1. Prevalence of eGFR<60ml/min/1.73m2 by age grouping and serum creatinine eGFR estimatingmethod.
doi:10.1371/journal.pone.0118676.g001
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Discussion
This study provides the first population-level comparison of low eGFR defined by serum creati-
nine-based (MDRD and CKDEPI) equations and by cystatin C in England; the first descrip-
tions of the distribution and associations of serum cystatin C concentration; and the potential
effects of its targeted use to improve risk stratification.
It suggests that the prevalence of eGFR<60ml/min/1.73m2 in England would be lower by
0.8% if the CKDEPI equation was introduced to classify CKD, equivalent to about 340,000
fewer people. Estimated CKD prevalence would be reduced in all age groups except in people
over 75, and those still classified as CKD would be at higher risk of adverse consequences, as
others have found.[13,20,22,24] This study also adds that targeted use of cystatin C in people
with one or two abnormal biomarkers (Scr-based eGFR<60ml/min/1.73m2 and / or
uACR3mg/mmol, about 12% of the population in this study) would further reduce the esti-
mated prevalence of people labelled as having CKD and likely improve their risk stratification.
Fig 2. Effect of the use of different combinations of measures on the risk profile and estimated prevalence of CKD.
doi:10.1371/journal.pone.0118676.g002
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Several other studies have reported a lower prevalence of CKD G3–5 with the use of the
CKDEPI equation. In the Australian Diabetes, Obesity and Lifestyle Study, CKDEPI reclassi-
fied approximately 1.9% of individuals as not having CKD G3–5 compared with MDRD.[32]
In the study by O’Callaghan and colleagues in the UK, the change of equation fromMDRD to
CKDEPI resulted in a reduction in the number of people with eGFR<60ml/min/1.73m2 from
27,579 to 25,504 out of 321,964 tests (a relative fall of 7.5%), resulting in a reduction in preva-
lence of approximately 1.2% of all patients tested. Our study suggests a more modest reduction
in prevalence, probably because it was representative of the population as a whole, rather than
being conducted on routine specimens as in the O’Callaghan study [13] and thus included a
higher proportion of individuals with no CKD. On the other hand, Cystatin C-based methods
alone would classify a higher proportion of the population as having eGFR<60ml/min/1.73m2,
and therefore CKD G3–5, compared with Scr, both using the Grubb equation to derive eGFR,
or using cystatin C directly with a threshold level, especially in older people. This is consistent
with data from NHANES in the US showing that the prevalence of elevated cystatin C levels in-
creased dramatically with age, with over 50% of those older than 80 having elevated levels.[21]
Analyses of CKD prevalence trends in NHANES suggest higher prevalence of CKD G3–5 de-
rived from cystatin C than from creatinine based equations.[33]
We identified significant associations between elevated cystatin C and increasing age, lower
qualification, smoking, higher BMI, diabetes, hypertension, raised total cholesterol, lower HDL
cholesterol, and albuminuria after adjusting for age and sex, although not all of these associa-
tions remained on full adjustment. In our study, the associations of elevated cystatin C and
Grubb-defined eGFR<60ml/min/1.73m2 were very similar. Similar associations with elevated
cystatin C (using a threshold method) were identified in NHANES (older age, hypertension,
current smoking, higher BMI, and higher triglyceride levels).[21] Cystatin C has been
Table 3. Characteristics of populations with selected combinations of biomarkers following testing with cystatin C.
Number of abnormal
biomarkers
1 2 3
Biomarker combinations Albuminuria
alone
Creatinine
<60 ml/min/
1.73m2
alone
Albuminuria
& Cystatin C
<60 ml/min/
1.73m2
Creatinine &
Cystatin C
<60 ml/min/
1.73m2
Albuminuria
& Creatinine
<60 ml/min/
1.73m2
Albuminuria
+ Cystatin C
& Creatinine
<60 ml/min/
1.73m2
Total in category 321 / 5260 77 / 5260 34 / 5260 130 / 5260 66 / 5260 57 / 5260
% of total (95% conﬁdence
intervals)
6.1 (5.5–6.8) 1.5 (1.1–1.8) 0.6 (0.4–0.9) 2.5 (2.1–2.9) 1.3 (1.0–1.6) 1.1 (0.8–1.4)
n % n % n % n % n % n %
Sex Male 161 50.2 24 31.2 23 67.6 57 43.8 36 54.5 30 52.6
Female 160 49.8 53 68.8 11 32.4 73 56.2 30 45.5 27 47.4
Age 16–54 192 59.8 13 16.9 4 11.8 3 2.3 1 2.2 4 8.0
55+ 129 40.2 64 83.1 30 88.2 127 97.7 65 97.8 53 92.0
Diabetes (total) 49 15.3 5 6.5 3 8.8 33 25.4 22 33.3 19 33.2
Hypertension (total) 191 59.5 54 70.1 28 82.4 117 90.0 56 85.8 48 84.8
BMI <25 97 32.4 15 22.1 6 24.0 10 7.7 12 21.7 10 21.7
25 to <30 117 39.1 28 41.2 10 40.0 44 33.8 24 45.2 21 45.7
30 85 28.5 25 36.7 9 36.0 47 36.2 18 33.1 15 32.6
BMI: Body Mass Index
doi:10.1371/journal.pone.0118676.t003
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Table 4. Estimated prevalence and associations of cystatin C CKD 3–5 (Grubb-deﬁned eGFR <60ml/min/1.73m2) with socio-economic and
clinical factors.
Variable Estimated prevalence of cystatin C
(Grubb) eGFR <60ml/min/1.73m2
Associations of cystatin C (Grubb) eGFR <60ml/min/
1.73m2
Univariate Age sex
adjusted
Multivariable†
Row % OR (95%CI) OR (95%CI) OR (95%CI)
Sex Male 7.5 1 1 1
Female 7.9 1.06 (0.87–1.29) 0.87 (0.69–1.08) 0.89 (0.66–1.20)
Age 16–34 0.7 1 1 1
34–54 1.9 3.62 (1.82–7.21)
**
3.61 (1.81–7.20)
**
3.02 (1.41–6.45) **
55–64 6.3 12.44 (6.35–
24.38)**
12.46 (6.36–
24.43) **
7.53 (3.50–16.22)
**
65–74 15.9 33.63 (17.50–
64.64)**
33.72 (17.54–
64.82) **
19.19 (9.06–40.68)
**
75+ 44.3 140.37 (79.94–
266.48)**
142.24 (74.89–
270.17) **
77.38 (36.44–
164.29) **
Qualiﬁcation Degree 2.1 1 1 1
Below
degree
5.3 2.61 (1.74–3.93)
**
2.16 (1.40–3.33)
**
1.91 (1.16–3.14)*
None 20.3 11.84 (7.90–
17.75) **
3.35 (2.16–5.20)
**
2.67 (1.60–4.45) **
Smoker Never 5.8 1 1 1
Ex 12.9 2.40 (1.94–2.98)
**
2.42 (1.75–3.34)
**
2.21 (1.51–3.23) **
Current 6.4 1.11 (0.85–1.47)
**
1.41 (1.1–1.81)
**
1.23 (0.91–1.67)
BMI Normal 3.8 1 1 1
Overweight 6.9 1.86 (1.39–2.48)
**
1.32 (0.96–1.83) 1.35 (0.94–1.95)
Obese 9.9 2.77 (2.06–3.71)
**
2.16 (1.55–3.00)
**
1.93 (1.30–2.85) **
Diabetes (doctor
diagnosed)
No 6.7 1 1 1
Yes 24.3 4.08 (3.07–5.42)
**
2.19(1.58–3.05)
**
1.73 (1.15–2.60) **
Hypertension (doctor
diagnosed)
No 4.3 1 1 1
Yes 18.0 4.91 (4.02–5.99)
**
1.74 (1.39–2.19)
**
1.45 (1.10–1.93)*
Albuminuria None 6.2 1 1 1
Micro 20.9 3.99 (3.05–5.21)
**
2.29 (1.66–3.15)
**
1.96 (1.36–2.82) **
Macro 31.8 6.83 (2.74–16.99)
**
7.19 (2.36–21.90)
**
6.97 (2.22–21.93)
**
Total cholesterol
(mmol/L)
Continuous 8.5 1 1 1
7.0 1.24 (1.02–1.51)
**
1.11 (1.01–1.22)
*
1.01 (0.89–1.13)
(Continued)
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associated with overweight and obesity in the general population,[34] and with the metabolic
syndrome in people with dyslipidaemias independent of serum creatinine.[35] Several studies
have demonstrated that cystatin C identifies people at higher risk of CKD progression and
complications more strongly than Scr eGFR.[20,24,36] Despite these advantages, the higher
prevalence of people labelled as having CKD, the higher cost of cystatin C assay and the lack of
specificity for CKD are likely to make the use of cystatin C as the first line measure of kidney
function (or as a screening tool for CKD) impractical, but it might have an important role in
risk stratification in those with CKD defined by Scr eGFR and uACR, as recommended in the
revised NICE guidelines.[12]
Non GFR determinants of cystatin C have been recognised as a limitation for its individual
prognostic value.[37] However, several studies in a variety of populations have shown the value
of adding cystatin C to existing markers as part of assessing risk in people with CKD.[20,36,38]
In the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a prospec-
tive cohort of over 26,000 adults, Peralta et al demonstrated the value of a triple marker ap-
proach using creatinine, uACR and cystatin C to identify people at higher risk of both
mortality and CKD progression.[24] Abnormality of all three biomarkers was associated with
the highest risk of all-cause mortality (HR 5.6 (95% confidence interval 3.9–8.2)) in the Peralta
study, and risks were similar for those with CKD defined by creatinine and uACR(HR 3.3 (95%
confidence interval 2.0–5.6)) and those defined by creatinine and cystatin C (HR 3.2 (95% con-
fidence interval 2.2–4.7)). A similar pattern was seen for incident ESKD.[24] In a meta-analysis
of 11 general population studies with over 90,000 participants, the CKD Prognosis Consortium
has demonstrated that use of cystatin C in combination with creatinine strengthens the associa-
tion between eGFR and risk of death or end stage kidney disease.[39] Revised UK NICE CKD
guidelines propose the use of cystatin C in those with Scr eGFR 45–59ml/min/1.73m2 and
uACR<3mg/mmol if confirmation of CKD is required.[12] Although we were unable to dem-
onstrate the link with clinical outcomes because of the cross sectional nature of the HSE, our
study suggests that a significant proportion (about a third) of people in England currently de-
fined as having CKD category G3a by creatinine based eGFR alone (CKDEPI) could be strati-
fied as being at lower risk by such targeted use of cystatin C testing. This would help allay some
Table 4. (Continued)
Variable Estimated prevalence of cystatin C
(Grubb) eGFR <60ml/min/1.73m2
Associations of cystatin C (Grubb) eGFR <60ml/min/
1.73m2
Univariate Age sex
adjusted
Multivariable†
Row % OR (95%CI) OR (95%CI) OR (95%CI)
HDL cholesterol (mmol/
L)
Continuous 9.5 1 1 1
7.2 1.35 (1.09–1.68)
**
1.89 (1.42–2.52)
**
1.32 (0.92–1.88)
† Adjusted for age, sex, qualiﬁcation, smoking, BMI, Doctor-diagnosed-hypertension and diabetes, albuminuria, total cholesterol, HDL cholesterol and
HBA1c.
* p<0.05
**p<0.01
BMI: Body Mass Index
HDL: High Density Lipoprotein
OR: Odds ratio
eGFR: Estimated glomerular ﬁltration rate.
doi:10.1371/journal.pone.0118676.t004
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of the current concerns of over diagnosis and inappropriate disease labelling.[8] We also iden-
tified a small sub group at increased risk from the larger group with CKD G1–2. Such risk strat-
ification would provide information for better targeting of interventions such as improved
blood pressure control, use of renin angiotensin aldosterone system inhibitors, cardiovascular
risk reduction and acute kidney injury (AKI) avoidance. Addition of cystatin C might also im-
prove current risk stratification models that have greater utility in predicting CKD progression
than cardiovascular risk.[40] The cost of cystatin C testing in routine practice has not been as-
sessed in this study but the revised NICE CKD guidance included economic analysis.[41] This
estimated that, while increased cystatin C testing increases the costs of CKD diagnosis, the fall
in the number of people requiring treatment and monitoring is likely to result in overall cost
saving.[41] Patients with an eGFR of<60 ml/min/1.73m2 are currently listed on primary care
kidney disease registers which form part of the incentive payment Quality and Outcomes
Framework (QOF) funding arrangement in England.[42] Reduced prevalence of CKD G3–5
could therefore result in reduced incentive payments to General Practitioners. This could be
addressed by a higher payment for the smaller number assessed more accurately.
Strengths and limitations
The HSE 2009 and 2010 are nationally representative samples, pooled over two years to in-
crease numbers and precision of estimates. There were standardised protocols for measure-
ment by trained interviewers and nurses. All samples were tested in the same laboratory with
standardised assays, which overcomes issues of selective testing in routine practice. There was
weighting for non-response to reduce response bias.
However the study was limited by its cross-sectional nature, which restricts the ability to
infer causal relationships from the associations identified. While we have shown that cystatin C
is associated with important risk factors (and thus may improve risk stratification), we could
not analyse its independent predictive capacity and can therefore not be certain that it would
improve CKD risk stratification. However, other studies such as that by Peralta et al strongly
suggest that it would.[24] Although no ‘gold standard’ measure of GFR was available to assess
‘true’ prevalence, that will always be the case for large, general population surveys and indeed is
what occurs in routine practice. In addition, only a single blood sample was taken for measure-
ment of serum cystatin C and creatinine, and a single sample of urine tested for uACR. Fluctua-
tions in creatinine have been shown to have a strong influence on CKD prevalence.[43]
Generalizability is also limited by the assay used to determine cystatin C value (the particle-
enhanced turbidimetric assay (PETIA)) and the manufacturer’s recommended equation to de-
rive eGFR (Grubb), in contrast to the majority of previous studies that have used the particle-
enhanced nephelometric assay (PENIA). Biases have been demonstrated between these assays;
PETIA cystatin C values were 27.5% higher than PENIA results and PENIA results were 12.9%
lower in 2010 than in 2000.[44] Such findings have led to calls for standardisation of cystatin C
assays.[45] Recent development of a CKDEPI creatinine-cystatin C equation (an eGFR equa-
tion combining cystatin C with standardised serum creatinine) using PENIA has demonstrated
improved diagnostic accuracy of the combined equation compared with either marker alone
for measured GFR.[23] We were unable to use the CKDEPI-cystatin C eGFR equation or this
combined equation due to the PETIA cystatin C assay method used, though the different meth-
ods have shown similar characteristics in predicting cardiovascular outcomes.[46]
Prevalence of category G4 and 5 CKD is likely to be underestimated as, while the HSE is
able to adjust for non-response among the general population in private households, it may
not fully account for some in whommore severe CKD (category G4 and 5) will be more com-
mon. This would include those who were not able to give a blood or urine sample because of
Using NewMeasures to Estimate CKD Prevalence in England
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poor health and those who did not participate due to concurrent illness or hospitalisation, as
well as those who were in residential care.
Conclusion
In this nationally representative population based study, estimated prevalence of CKD was
lower using the CKDEPI equation to classify CKD rather than the currently used MDRD equa-
tion, and those identified were likely to be at higher risk of complications and kidney disease
progression. Selected use of cystatin C may further improve risk stratification, and address
some of the current concerns about over diagnosis and over treatment of CKD G3.
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